Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen–negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2016-11, Vol.214 (10), p.1492-1497
Main Authors: zu Siederdissen, Christoph Höner, Rinker, Franziska, Maasoumy, Benjamin, Wiegand, Steffen B., Filmann, Natalie, Falk, Christine S., Deterding, Katja, Port, Kerstin, Mix, Carola, Manns, Michael P., Herrmann, Eva, Wedemeyer, Heiner, Kraft, Anke R. M., Cornberg, Markus
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antiviral Agents - administration & dosage
Cytokines - blood
DNA, Viral - blood
Female
Hepatitis B Core Antigens - blood
Hepatitis B e Antigens - blood
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - pathology
Hepatitis B, Chronic - virology
Humans
Male
Middle Aged
Nucleosides - administration & dosage
Nucleotides - administration & dosage
Prospective Studies
Recurrence
VIRUSES
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen–negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was associated with induction of plasma tumor necrosis factor, interleukin (IL) 10, IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-term follow-up. The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of therapy were positively correlated with the level of HBsAg decline at week 48. Thus, stopping or interrupting NA treatment should be further investigated as a strategy to accelerate HBsAg loss.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiw412